MB
MPM BioImpact Portfolio holdings
AUM
$577M
This Quarter Return
+11.01%
1 Year Return
+8.33%
3 Year Return
+241.63%
5 Year Return
+127.38%
10 Year Return
–
AUM
$385M
AUM Growth
+$385M
(-0.14%)
Cap. Flow
+$13.9M
Cap. Flow
% of AUM
3.62%
Top 10 Holdings %
Top 10 Hldgs %
70.32%
Holding
34
New
1
Increased
10
Reduced
11
Closed
3
Top Buys
| 1 |
Relay Therapeutics
RLAY
|
$20.2M |
| 2 |
PRVB
Provention Bio, Inc. Common Stock
PRVB
|
$6.64M |
| 3 |
Intellia Therapeutics
NTLA
|
$4.37M |
| 4 |
Iovance Biotherapeutics
IOVA
|
$2.84M |
| 5 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
$2.73M |
Top Sells
| 1 |
uniQure
QURE
|
$11.9M |
| 2 |
Harmony Biosciences
HRMY
|
$7.68M |
| 3 |
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
|
$3.53M |
| 4 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$1.78M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$1.62M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cullinan Oncology
CGEM
$445M
| $78.2M | 20.33% | 7,648,268 | – | – |
|
|
PRVB
2
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $28.3M | 7.35% | 1,173,809 +275,326 | +31% | +$6.64M |
|
|
ISEE
3
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $25.4M | 6.61% | 1,045,691 -13,997 | -1% | -$341K |
|
4
iTeos Therapeutics
ITOS
| $23.8M | 6.17% | 1,745,943 | – | – |
|
|
INBX
5
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $22.5M | 5.85% | 1,192,281 -94,154 | -7% | -$1.78M |
|
|
6
Intellia Therapeutics
NTLA
$1.22B
| $21.3M | 5.54% | 572,459 +117,221 | +26% | +$4.37M |
|
|
7
Relay Therapeutics
RLAY
$619M
| $20.2M | 5.24% | +1,225,634 | New | +$20.2M |
|
8
Geron
GERN
$893M
| $18.2M | 4.74% | 8,401,565 -65,416 | -0.8% | -$142K |
|
|
RETA
9
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $16.5M | 4.3% | 176,874 -17,307 | -9% | -$1.62M |
|
10
Repare Therapeutics
RPTX
$71.7M
| $16.1M | 4.19% | 1,639,849 | – | – |
|
|
11
Iovance Biotherapeutics
IOVA
$807M
| $16M | 4.15% | 2,614,977 +465,427 | +22% | +$2.84M |
|
12
Regenxbio
RGNX
$451M
| $11.7M | 3.03% | 617,671 -3,701 | -0.6% | -$70K |
|
|
VERV
13
DELISTED
Verve Therapeutics
VERV
| $11.6M | 3.01% | 803,501 -5,160 | -0.6% | -$74.4K |
|
14
Madrigal Pharmaceuticals
MDGL
$9.76B
| $8.73M | 2.27% | 36,038 +9,265 | +35% | +$2.24M |
|
15
Travere Therapeutics
TVTX
$1.56B
| $7.05M | 1.83% | 313,642 +31,931 | +11% | +$718K |
|
|
16
uniQure
QURE
$896M
| $7.01M | 1.82% | 348,224 -591,742 | -63% | -$11.9M |
|
17
Insmed
INSM
$28.8B
| $6.81M | 1.77% | 399,192 -11,271 | -3% | -$192K |
|
18
Werewolf Therapeutics
HOWL
$59.9M
| $6.21M | 1.61% | 2,388,011 | – | – |
|
19
Crinetics Pharmaceuticals
CRNX
$2.92B
| $5.79M | 1.5% | 360,392 -11,247 | -3% | -$181K |
|
20
Revolution Medicines
RVMD
$7.1B
| $5.35M | 1.39% | 247,022 +97,979 | +66% | +$2.12M |
|
|
TCRR
21
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $5.06M | 1.31% | 3,370,982 | – | – |
|
|
KDNY
22
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $4.58M | 1.19% | 197,806 +117,806 | +147% | +$2.73M |
|
23
Axsome Therapeutics
AXSM
$6.05B
| $4.34M | 1.13% | 70,402 +18,427 | +35% | +$1.14M |
|
24
Amicus Therapeutics
FOLD
$2.34B
| $4.31M | 1.12% | 388,292 -12,118 | -3% | -$134K |
|
25
Arcutis Biotherapeutics
ARQT
$1.86B
| $2.8M | 0.73% | 254,137 -7,932 | -3% | -$87.3K |
|